Header Image
News Room / Bank of America Suspends Plans for Buy Back and Dividend Increase; Sprint Falls on New FCC Rules

Bank of America Suspends Plans for Buy Back and Dividend Increase; Sprint Falls on New FCC Rules

Bank of America Corporation (NYSE: BAC) – For an in-depth report on Bank of America Corporation follow: www.BullTrends.com/stockquote/BAC

Shares of Bank of America closed down nearly 7% on Monday and was one of the biggest decliners in the NYSE. The stock traded nearly 345 million shares, which was significantly higher than usual trading volume. The company announced that it made an “incorrect adjustment” on investments acquired along with Merril Lynch five years ago. The company wanted to buy back $4B in stock and increase its dividend but the Federal Reserve told the bank to suspend plans to buy back shares and raise its dividend.

Apple Inc. (NASDAQ: AAPL) – For an in-depth report on Apple Inc. follow: www.BullTrends.com/stockquote/AAPL

Shares of Apple Inc. closed up 3.87% on Monday with nearly 24 million shares traded. Apple was one of the most active stocks on the NASDAQ. Shares have risen 12% over the past three days. The company also recently added $30 billion to its stock-buyback plan, raised its dividend about 8%.

Sprint Corporation (NYSE: S) – For an in-depth report on Sprint Corporation follow: www.BullTrends.com/stockquote/S

Shares of Sprint closed down nearly 5% on Monday with about 33.2 million shares traded. The decline came after a report revealed that new FCC rules would make it harder for the wireless carrier to make deals for spectrum.

Brainstorm Cell Therapeutics Inc. (OTCBB: BCLI) – For an in-depth report on Brainstorm Cell Therapeutics Inc. follow: www.BullTrends.com/stockquote/BCLI

Shares of BCLI closed up 6.79% with about 3.7 million shares traded on Monday. The stock had one of the biggest volume advances and was one of the biggest percentage advancers in the OTCBB marketplace, The US Food and Drug Administration (FDA) has approved commencement of the company’s Phase II clinical trial with NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS).


Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.